TAVR Highlights: AI alerts make a big impact | When PCI can wait | A key FDA approval | New stroke prevention tech | AKI risks

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

The Trilogy Transcatheter Heart Valve System is the first TAVR device approved by the FDA to treat severe aortic regurgitation. Until now, interventional cardiologists have had to settle for the off-label use of TAVR valves built for treating aortic stenosis. 

A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate. 

The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities. 

Multiple studies have linked acute kidney injury after TAVR to a heightened risk of short- and long-term mortality. 

New pacing system is designed to streamline TAVR cath lab workflows, cut procedural steps and increase reliability.

Cleveland Clinic, one of the world’s top heart hospitals, has launched a new two-part partnership with Ohio-based DASI Simulations.